SCHEDULE: Vanguard Boosts Myriad Genetics Stake to 8.47%
Beneficial Ownership Report
The Vanguard Group has filed an amended Schedule 13G, reporting a beneficial ownership of 8.47% in Myriad Genetics Inc. common stock.
Summary
- The Vanguard Group reported beneficial ownership of 7,882,515 shares of Myriad Genetics Inc. common stock.
- This ownership represents 8.47% of the class of securities.
- Vanguard holds sole dispositive power over 7,069,696 shares and shared dispositive power over 812,819 shares.
- Vanguard has shared voting power over 723,379 shares and no sole voting power.
- The filing is an Amendment No. 13 to a previous Schedule 13G statement.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership by a large institutional investor. While a significant stake can be seen as a positive signal, the filing itself does not contain new operational or financial information about Myriad Genetics Inc. that would dramatically shift sentiment. The 'Date of Event' being in the future is unusual but is reported as stated in the document.
Positives
- The Vanguard Group, a major institutional investor, maintaining a significant stake (8.47%) in Myriad Genetics Inc. may signal continued institutional confidence in the company.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing reflects a routine disclosure of an institutional investor's stake in a publicly traded company within the biotechnology and diagnostics sector. Such filings are common and provide transparency regarding significant ownership positions, which can influence market perception of a company's stability and investor interest.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The continued significant ownership by The Vanguard Group may provide a level of confidence to other shareholders regarding institutional interest in Myriad Genetics Inc.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement |
| 10/31/2025 | Signature date of the filing by The Vanguard Group |
Keywords
Myriad Genetics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.